Sk Biopharmaceuticals Co., Ltd.

Sk Holdings Co., Ltd.

Sun Gwan Hwang

Han Ju Yi

Sung Jin Bae

Ji Won Lee

Chan Mi Joung

Young Koo Jang

Tae Sung Koo

Sang Rak Choi

Jeong Woo Cho

Kyung Chul Cho

Min Jae Jo

So Young Lee

Yeo Jin Yoon

Jihye Kim

Eun Ju Ryu

Sang Mi Chae

Joo Young Park

Hyeon Cheol Gwon

Mo Ses Jeong

Jimok Yoon

The present invention relates to use of a carbamate compound of Formula 2 for the purpose of preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy by administering a pharmaceutical composition comprising a carbamate compound of Formula 2.

Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy

The present invention relates to a blend for prevention, mitigation, or treatment of schizophrenia, the blend containing a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and, more specifically, to a blend and a pharmaceutical composition each containing a carbamate compound of chemical formula 1 and aripiprazole, and to a use thereof for treating schizophrenia.

Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia

The present invention relates to a pharmaceutical composition for preventing or treating trigeminal neuralgia, the pharmaceutical composition comprising: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, a solvate or a hydrate; and a pharmaceutically acceptable carrier. The pharmaceutical composition, according to the present invention, may enable the efficient prevention or treatment of trigeminal neuralgia.

Use of carbamate compound for preventing or treating trigeminal neuralgia

The present invention relates to a use for preventing, alleviating or treating a demyelinating disease by administering a pharmaceutical composition containing a carbamate compound of chemical formula 1.

Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease

The present invention relates to a pharmaceutical composition for preventing or treating fibromyalgia or a functional syndrome associated with fibromyalgia, the pharmaceutical composition comprising: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, a solvate or a hydrate; and a pharmaceutically acceptable carrier. The pharmaceutical composition, according to the present invention, may enable the efficient treatment of fibromyalgia or a functional syndrome associated with fibromyalgia.

Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia

A novel methylcyclohexane derivative, and a pharmaceutical composition including the same that is effective for the prevention or treatment of pain.

Methylcyclohexane derivatives and uses thereof

There is provided a pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives. The pharmaceutical composition includes a therapeutic effective amount of isoxazole derivatives represented by Formula 1 or pharmaceutically available salts thereof. The pharmaceutical composition may be useful to prevent and treat vascular restenosis since the pharmaceutical composition shows an anti-restenosis activity and accelerates the re-endothelization.

Pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives

Disclosed herein are isoxazole derivatives and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/&#x3b2;-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.

Growing community of inventors

Gyeonggi-do, South Korea

Sun Gwan Hwang